HK1213821A1 - 抗微生物組合物 - Google Patents

抗微生物組合物

Info

Publication number
HK1213821A1
HK1213821A1 HK16101991.9A HK16101991A HK1213821A1 HK 1213821 A1 HK1213821 A1 HK 1213821A1 HK 16101991 A HK16101991 A HK 16101991A HK 1213821 A1 HK1213821 A1 HK 1213821A1
Authority
HK
Hong Kong
Prior art keywords
antimicrobial compositions
antimicrobial
compositions
Prior art date
Application number
HK16101991.9A
Other languages
English (en)
Inventor
丹平．李
艾瑞克．
．布拉卡
大衛．
．德瑞斯巴克
丹尼爾．博伊雷爾．路德
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1213821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of HK1213821A1 publication Critical patent/HK1213821A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
HK16101991.9A 2008-11-15 2016-02-23 抗微生物組合物 HK1213821A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19925308P 2008-11-15 2008-11-15

Publications (1)

Publication Number Publication Date
HK1213821A1 true HK1213821A1 (zh) 2016-07-15

Family

ID=42170697

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101991.9A HK1213821A1 (zh) 2008-11-15 2016-02-23 抗微生物組合物

Country Status (24)

Country Link
US (4) US20120065186A1 (zh)
EP (1) EP2373166A4 (zh)
JP (3) JP6063123B2 (zh)
KR (1) KR101767689B1 (zh)
CN (3) CN102215690B (zh)
AU (1) AU2009314072C1 (zh)
BR (2) BR122020021551B1 (zh)
CA (1) CA2743419C (zh)
CO (1) CO6382082A2 (zh)
CR (1) CR20110320A (zh)
EA (1) EA025637B1 (zh)
EC (1) ECSP11011119A (zh)
HK (1) HK1213821A1 (zh)
IL (1) IL212781A (zh)
MA (1) MA32931B1 (zh)
MX (1) MX2011005117A (zh)
MY (3) MY161597A (zh)
NI (1) NI201100097A (zh)
NZ (1) NZ593345A (zh)
PE (2) PE20120029A1 (zh)
SV (1) SV2011003907A (zh)
UA (1) UA102709C2 (zh)
WO (1) WO2010056872A2 (zh)
ZA (1) ZA201104108B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2743419C (en) * 2008-11-15 2017-02-14 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
EP2785352B1 (en) * 2011-11-29 2020-03-11 Jurox Pty Ltd Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
JP6395200B2 (ja) * 2012-10-22 2018-09-26 ジェクス株式会社 ケイ素含有化合物水溶液及び該水溶液を含む抗菌・抗ウィルス剤
AU2014225392A1 (en) * 2013-03-08 2015-09-24 Melinta Therapeutics, Inc. Crystalline forms of D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate
EP2969004A4 (en) * 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2017159585A1 (ja) 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
CN107789324B (zh) * 2016-08-31 2021-05-25 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺及其制备方法
CN107789323B (zh) * 2016-08-31 2021-05-07 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
WO2018151177A1 (ja) * 2017-02-15 2018-08-23 大鵬薬品工業株式会社 医薬組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US436A (en) 1837-10-23 Brick mold used in brick-pressing machines
US5998A (en) 1849-01-02 Improvement in combined plows
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
BR9610485B8 (pt) 1995-09-22 2014-08-05 Wakunaga Pharma Co Ltd Derivados de ácido piridono carboxílico ou seus sais, e agentes antibacteriais contendo os mesmos como seus componentes efetivos.
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
ES2506143T3 (es) 2004-07-30 2014-10-13 Abbvie Inc. Preparación de sustancias antibacterianas de ácido piridonacarboxílico
MX2007004111A (es) 2004-10-08 2007-06-14 Abbott Lab Sal y formas cristalinas de la misma de un farmaco.
ATE549016T1 (de) * 2005-04-11 2012-03-15 Abbott Lab Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070238720A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CA2743419C (en) * 2008-11-15 2017-02-14 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions

Also Published As

Publication number Publication date
WO2010056872A3 (en) 2010-07-29
US20160235736A1 (en) 2016-08-18
IL212781A (en) 2016-12-29
BRPI0921705A2 (pt) 2015-08-25
JP6407221B2 (ja) 2018-10-17
CR20110320A (es) 2011-10-18
BRPI0921705B8 (pt) 2021-05-25
CN102215690B (zh) 2015-07-01
AU2009314072C1 (en) 2016-11-10
KR101767689B1 (ko) 2017-08-11
CO6382082A2 (es) 2012-02-15
NZ593345A (en) 2013-04-26
CA2743419A1 (en) 2010-05-20
CA2743419C (en) 2017-02-14
KR20120008020A (ko) 2012-01-25
CN103705942A (zh) 2014-04-09
BRPI0921705B1 (pt) 2021-01-19
UA102709C2 (uk) 2013-08-12
MY188453A (en) 2021-12-09
CN102215690A (zh) 2011-10-12
US20200022971A1 (en) 2020-01-23
CN103705942B (zh) 2016-08-24
EA201170689A1 (ru) 2013-10-30
ZA201104108B (en) 2012-09-26
EA025637B1 (ru) 2017-01-30
MY161597A (en) 2017-04-28
CN104958296A (zh) 2015-10-07
EP2373166A2 (en) 2011-10-12
SV2011003907A (es) 2011-12-06
US20120065186A1 (en) 2012-03-15
AU2009314072A1 (en) 2011-06-30
MX2011005117A (es) 2011-10-21
US20220265636A1 (en) 2022-08-25
MY194407A (en) 2022-11-30
JP6063123B2 (ja) 2017-01-18
CN104958296B (zh) 2017-12-01
BR122020021551B1 (pt) 2021-09-21
PE20120029A1 (es) 2012-02-13
WO2010056872A2 (en) 2010-05-20
AU2009314072B2 (en) 2016-05-19
JP2012508757A (ja) 2012-04-12
PE20160116A1 (es) 2016-03-09
EP2373166A4 (en) 2014-11-05
JP2015091856A (ja) 2015-05-14
MA32931B1 (fr) 2012-01-02
ECSP11011119A (es) 2011-11-30
IL212781A0 (en) 2011-07-31
JP2017031164A (ja) 2017-02-09
NI201100097A (es) 2011-09-08

Similar Documents

Publication Publication Date Title
HK1157665A1 (zh) 抗微生物組合物
HK1246216B (zh) 抗微生物組合物
GB2473460B (en) Antimicrobial Composition
ZA201102078B (en) An antimicrobial composition
GB0823265D0 (en) Antimicrobial Composition
HK1213821A1 (zh) 抗微生物組合物
GB0713799D0 (en) Anti-microbial compositions
IL209794A0 (en) Fungicidal compositions
PL2634232T3 (pl) Kompozycje
GB0810404D0 (en) Compositions
EP2182811A4 (en) ANTIMICROBIAL COMPOSITIONS
GB0800760D0 (en) Fungicidal compositions
HK1159668A1 (en) Multi-cure compositions
GB0812041D0 (en) Compositions
PL2303024T3 (pl) Kompozycje biobójcze
GB0808537D0 (en) Compositions
PL2276484T3 (pl) Mieszanina o działaniu przeciwdrobnoustrojowym
GB0818804D0 (en) Compositions
ZA201005683B (en) Topical antimicrobial compositions
EP2341886A4 (en) ANTIMICROBIAL N-CHLORINE COMPOSITIONS
GB0822837D0 (en) Fungicidal compositions
EP2170081A4 (en) ANTIMICROBIAL COMPOSITIONS
GB0819623D0 (en) Antimicrobial composition
GB0801946D0 (en) Anti-microbial compositions
GB0901693D0 (en) Antimicrobial composition